Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174217
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Benavent Palomares, Eva | - |
dc.contributor.author | Morata, Laura | - |
dc.contributor.author | Escrihuela Vidal, Francesc | - |
dc.contributor.author | Reynaga, Esteban Alberto | - |
dc.contributor.author | Soldevila, Laura | - |
dc.contributor.author | Albiach, Laia | - |
dc.contributor.author | Pedro Botet, Maria Luisa | - |
dc.contributor.author | Padullés Zamora, Ariadna | - |
dc.contributor.author | Soriano Viladomiu, Alex | - |
dc.contributor.author | Murillo Rubio, Óscar | - |
dc.date.accessioned | 2021-02-24T14:42:21Z | - |
dc.date.available | 2021-02-24T14:42:21Z | - |
dc.date.issued | 2021-01-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174217 | - |
dc.description.abstract | Background: To evaluate the efficacy and safety of long-term use of tedizolid in osteoarticular infections. Methods: Multicentric retrospective study (January 2017–March 2019) of osteoarticular infection cases treated with tedizolid. Failure: clinical worsening despite antibiotic treatment or the need of suppressive treatment. Results: Cases (n = 51; 59% women, mean age of 65 years) included osteoarthritis (n = 27, 53%), prosthetic joint infection (n = 17, 33.3%), and diabetic foot infections (n = 9, 18%); where, 59% were orthopedic device-related. Most frequent isolates were Staphylococcus spp. (65%, n = 47; S. aureus, 48%). Reasons for choosing tedizolid were potential drug-drug interaction (63%) and cytopenia (55%); median treatment duration was 29 days (interquartile range -IQR- 15–44), 24% received rifampicin (600 mg once daily) concomitantly, and adverse events were scarce (n = 3). Hemoglobin and platelet count stayed stable throughout treatment (from 108.6 g/L to 116.3 g/L, p = 0.079; and 240 × 109/L to 239 × 109/L, p = 0.942, respectively), also in the subgroup of cases with cytopenia. Among device-related infections, 33% were managed with implant retention. Median follow-up was 630 days and overall cure rate 83%; among failures (n = 8), 63% were device-related infections. Conclusions: Long-term use of tedizolid was effective, showing a better safety profile with less myelotoxicity and lower drug-drug interaction than linezolid. Confirmation of these advantages could make tedizolid the oxazolidinone of choice for most of osteoarticular infections. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/antibiotics10010053 | - |
dc.relation.ispartof | Antibiotics, 2021, vol. 10, num. 1 | - |
dc.relation.uri | https://doi.org/10.3390/antibiotics10010053 | - |
dc.rights | cc by (c) Benavent Palomares et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Diabetis | - |
dc.subject.classification | Interaccions dels medicaments | - |
dc.subject.other | Diabetes | - |
dc.subject.other | Drug interactions | - |
dc.title | Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 720016 | - |
dc.date.updated | 2021-02-08T10:34:17Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33429902 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BenaventE.pdf | 667.75 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License